Blood Pressure in Heart Failure A Love-Hate Relationship⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. by Pfeffer, Marc A.
B
A
M
B
L
i
p
w
t
e
f
g
h
c
a
s
o
(
T
a
c
c
h
o
h
f
l
f
h
a
t
a
c
c
H
a
L
(
m
c
i
c
t
d
e
f
m
w
u
l
e
C
u
c
p
a
e
h
p
l
c
a
h
r
c
o
p
b
w
r
p
p
c
t
c
d
h
o
p
p
B
f
r
e
t
o
a
*
v
A
M
Journal of the American College of Cardiology Vol. 49, No. 1, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2006.10.028EDITORIAL COMMENT
lood Pressure in Heart Failure
Love-Hate Relationship*
arc A. Pfeffer, MD, PHD, FACC
oston, Massachusetts
owering blood pressure (BP) in patients with hypertension
s probably one of the most important population-based
reventive measures for heart failure. In caring for patients
ith hypertension, the sphygmomanometer remains the key
ool for titrating antihypertensive therapy to achieve and
nsure adequate BP lowering. Paradoxically, once heart
ailure is manifest, those with lower arterial pressures
enerally have a worse prognosis. Although our cornerstone
eart failure therapies, beta-blockers and angiotensin-
onverting enzyme inhibitors, are effective antihypertensive
gents in patients with impaired cardiac function, the
phygmomanometer is not generally used to assess adequacy
f these therapies. In this issue of the Journal, Anand et al.
1) from the A-HeFT (African-American Heart Failure
rial) study conducted a secondary analysis that showed an
pparent dissociation between the BP lowering effects of the
ombination of hydralazine and isosorbide dinitrate and its
linical efficacy in reducing the risk of death as well as
ospitalization for heart failure. A review of the convergence
f data regarding the use of antihypertensive therapies for
ypertension, after myocardial infarction, and for heart
ailure supports their findings and underscores that in the
atter 2 conditions, BP lowering is not an essential feature
or monitoring the effectiveness of therapy.
See page 32
In the 1950s, while the medical community considered
ypertension to be “essential” for organ perfusion, the
ctuarials of life insurance companies had already quanti-
ated the negative impact of higher BP on longevity and had
djusted premium rates accordingly (2). The concepts of
oronary heart disease risk factors born from decades of
areful epidemiologic observations from the Framingham
eart Study decisively establish the importance of elevated
rterial pressure as a risk for premature cardiac death (3).
ong-term follow-up data from the registry of MRFIT
Editorials published in the Journal of the American College of Cardiology reflect the
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merican College of Cardiology.r
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assachusetts. Dr. Pfeffer consulted for NitroMed for 1 day.Multiple Risk Factor Intervention Trial) of over 300,000
iddle-aged men also left an indelible imprint on physi-
ians regarding the graded hazard of higher arterial BPs (4).
Although hypertension is a promiscuous risk factor,
mportantly involved in the pathogenesis of most major
ardiovascular morbidities such as stroke, myocardial infarc-
ion, aneurysm formation, and rupture as well as the
evelopment of the syndrome of congestive heart failure,
levated BP is the major population-attributable risk factor
or heart failure. Indeed, recent estimates from the Fra-
ingham study indicate that in 40% of men and 60% of
omen persistent hypertension is the predominant contrib-
ting factor for the development of heart failure (5).
The full impact and the importance of these epidemio-
ogic observations could only be realized in the late 1960s to
arly 1970s, after the pioneering Veterans Administration
ooperative Studies. Led by the late Dr. Edward Fries and
sing the developing tool of the randomized placebo-
ontrolled trial, 2 Veterans Administration trials showed in
atients with severe hypertension that pharmacologic ther-
py to lower arterial pressure would reduce the risk of
xperiencing major cardiovascular events (6,7). From these
umble beginnings, many more extensive randomized
lacebo-controlled trials have firmly and irrefutably estab-
ished the importance of lowering BP to reduce cardiovas-
ular risk. Indeed, the benefits of antihypertensive therapy
re so clear that the era of placebo-controlled trials in
ypertension has been completed with definitive evidence of
eductions in risk of cardiovascular death, stroke, and myo-
ardial infarction and an approximate halving of the incidence
f heart failure (8–10). Today’s debates focus on whether a
articular class of antihypertensive therapy offers more clinical
enefits beyond its peripherally determined BP lowering effects
ithout any further question regarding the vital importance of
educing BP in patients with hypertension (11).
Despite these clear data showing that lower BP is better,
hysicians caring for critically ill patients, such as those
resenting with decompensated heart failure or acute myo-
ardial infarction, have had a very different perspective. In
hese settings, lower arterial pressure portends poor out-
omes (12–14), especially when coupled with clinical evi-
ence of pulmonary congestion, the hallmark of a tenuous
emodynamic condition produced by inadequate cardiac
utput. Even in less acute settings such as ambulatory
atients referred for cardiac transplant evaluation (15), or
articipants in heart failure clinical trials (16), lower arterial
P consistently emerges as an independent prognostic
actor for higher rates of death.
Approximately 3 decades ago, Cohn and Franciosa (17)
easoned that using an arterial vasodilator to reduce periph-
ral resistance could “unload” the failing left ventricle,
hereby improving stroke volume and cardiac output with-
ut necessarily further lowering arterial pressure. In animal
nd early human studies, he honed this concept of afterload
eduction with acute nitroprusside infusions. It is quite
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January 2/9, 2007:40–2 Editorial Commenttting that the V-HeFT (Veterans Administration Heart
ailure Trial) study served as the pioneers for testing this
nloading concept on ambulatory patients with symptom-
tic heart failure and depressed left ventricular function (18).
n this truly “classic” trial, there were 2 experimental
unloaded” groups, prazosin and the combination of hydral-
zine and isosorbide dinitrate in addition to placebo. In this
rst trial to show a favorable alteration in the prognosis of
atients with heart failure, survival was improved with the
ombination of hydralazine and isosorbide dinitrate, and the
ortality rate for the group on prazosin was similar to that
or placebo. However, at 1 year, BP change in the groups
ere0.3 mm Hg,0.6 mmHg, and4.6 mmHg in the
lacebo, hydralazine and isosorbide dinitrate, and prazosin
roups, respectively. This clear dissociation between BP
owering (greatest with prazosin, least with hydralazine and
sosorbide dinitrate) and clinical outcomes was an early
ndication that the benefit of using antihypertensive agents
n patients with heart failure was not necessarily reflected by
r related to changes in arterial BP. The MERIT-HF
Metoprolol CR/XL Randomized Intervention Trial in
ongestive Heart Failure) study provided another notable
xample whereby antihypertensive therapy (beta-blocker) in
atients with heart failure resulted in an increase in BP
ompared with placebo and, much more importantly, a
ajor improvement in survival (19). More recent improve-
ent in cardiac function with nonpharmacologic ap-
roaches to heart failure such as cardiac resynchronization
herapy in patients with a prolonged QRS duration further
llustrate the paradoxical but not currently unforeseen rela-
ionship between an increase in BP and improvement in
linical outcomes in these patients (20).
In this historical context, it has now been 2 decades after
he first demonstration of the efficacy of the combination of
ydralazine and isosorbide dinitrate was re-evaluated in a
ontemporarily relevant fashion, i.e., on top of angiotensin-
onverting enzyme inhibitors and beta-blockers (21) in an
frican-American population with New York Heart Asso-
iation functional class III and IV heart failure and reduced
ystolic function by the A-HeFT study investigators. Al-
hough the trial was designed with a complex combined
utcome of mortality, morbidity, and assessment of quality
f life primary efficacy measure, it was stopped before
cheduled completion by its safety monitoring committee
ecause of a clear reduction in the more straightforward
utcome of death. The new information from Anand et al.
1), indicating that although overall there was a lowering of
rterial pressure with the combined vasodilators, the improve-
ents in clinical outcomes were not related to the BP changes,
omes full circle with the original V-HeFT study (1,18).
That these seasoned heart failure investigators up-titrated
his potent antihypertensive regimen 3 to 5 days after random-
zation assessing tolerability by telephone clearly underscores
hat, in contrast to hypertension, the BP response was not a
herapeutic target in ambulatory heart failure patients. The
ord ambulatory is added as a qualifier and reminder that inore compromised patients with impaired cardiac function
here is a major concern of reducing central arterial pressure
elow autoregulatory ranges for cerebral, renal, or cardiac
erfusion. In this context, the treating physician “loves” every
m Hg and wants to administer vasodilators without produc-
ng a decrease in peripherally determined BP. However, in the
ajority of the walking well patients, the medical community
as learned to “hate” hypertension and we use the sphygmo-
anometer to direct therapy to prevent patients from devel-
ping hypoperfusing hypotensive conditions in which the same
gents are administered without the objection of reducing
rterial pressure. This apparent paradox underscores the fun-
amental tenet of the individualization of medical care.
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